Redaporfin

Drug Profile

Redaporfin

Alternative Names: LUZ-11

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bluepharma; Universidade de Coimbra
  • Developer Luzitin
  • Class Antineoplastics; Macrocyclic compounds; Porphyrins
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer

Most Recent Events

  • 02 Jun 2017 Adverse events, efficacy and pharmacokinetics data from a phase II trial in Head and neck cancer presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 15 Mar 2016 Phase-II clinical trials in Head and neck cancer (Late stage disease) in Portugal (IV)
  • 20 Feb 2014 Phase-I/II clinical trials in Head and neck cancer in Portugal (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top